Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProStrakan Group, Orexo's partner, have introduced a sublingual tablet, Abstral as a treatment for cancer pain in US market.
Subscribe to our email newsletter
Abstral , which is already marketed by ProStrakan across the European markets has got the US Food and Drug Administration approval in January 2011.
Abstral is based on Orexo’s sublingual tablet technology and the analgesic, fentanyl.
Orexo president and CEO Anders Lundstrom said they are pleased that Abstral has been launched on the US market for fast and effective relief from breakthrough pain.